Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register

(2012) Marieke H Otten et al.   ANNALS OF THE RHEUMATIC DISEASES

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis

(2012) Dirk Holzinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic juvenile idiopathic arthritis

(2012) Alberto Martini   AUTOIMMUNITY REVIEWS

Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles

(2012) Masaki Shimizu et al.   CYTOKINE

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO

(2012) K. Minden et al.   RHEUMATOLOGY

Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

(2012) Yukiko Kimura et al.   ARTHRITIS CARE & RESEARCH

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

(2011) Nicolino Ruperto et al.   ARTHRITIS AND RHEUMATISM

Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis

(2011) Marieke H. Otten et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Juvenile idiopathic arthritis

(2011) Berent Prakken et al.   LANCET

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

(2010) Joost Frans Swart et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

(2010) M. Shimizu et al.   RHEUMATOLOGY

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis

(2009) Michael Frosch et al.   ARTHRITIS AND RHEUMATISM

Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis

(2009) Wilco de Jager et al.   ARTHRITIS AND RHEUMATISM

Systemic JIA: new developments in the understanding of the pathophysiology and therapy

(2009) Sebastiaan J. Vastert et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis

(2009) Sebastiaan J. Vastert et al.   RHEUMATOLOGY

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms

(2008) Kejian Zhang et al.   ARTHRITIS AND RHEUMATISM